AUCTORES
Globalize your Research
Research Article | DOI: https://doi.org/10.31579/2641-0419/487
1Popular Medical College Hospital, Dhaka.
2National Institute of Cardiovascular Diseases, Dhaka.
3Beximco Pharmaceuticals Ltd., Dhaka.
4Rajshahi Medical College Hospital, Rajshahi
5Kurmitola General Hospital, Dhaka.
6Rangpur Medical College Hospital, Rangpur.
7Mount Adora Hospital, Sylhet.
8Ad-Din Akij Medical College Hospital, Khulna.
9Habiganj Medical College Hospital, Habiganj.
10Mymensingh Medical College Hospital, Mymensingh.
11Dinajpur Medical College Hospital, Dinajpur.
12South Apollo Medical College Hospital, Barishal.
13Square Hospital, Dhaka.
14Shaheed M. Monsur Ali Medical College, Sirajganj.
15Shaheed Tajuddin Ahmad Medical College Hospital, Gazipur.
16Enam Medical College Hospital, Dhaka.
17Naogaon Medical College Hospital, Naogaon.
18Nexus hospitals, Mymensingh.
19Bangladesh Medical University, Dhaka
20Sir Salimullah Medical College & Mitford Hospital, Dhaka
21Ibn Sina Diagnostic Center, Uttara.
22Chittagong Medical College Hospital, Chittagong.
23Rangamati Medical College Hospital, Rangamati
24Dhaka National Medical College Hospital, Dhaka
25Sheikh Sayera Khatun Medical College Hospital, Gopalganj.
26Shaheed Ziaur Rahman Medical College Hospital, Bogura.
27Hathazari Health Complex, Chittagong.
28Tangail Medical College Hospital, Tangail.
*Corresponding Author: Mohammed Alimur Reza, Beximco Pharmaceuticals Ltd., Dhaka.
Citation: Abdullah Al S M , Toufiqur Rahman , AKM Monowarul Islam , Mohammad U Firoz , Md. Alimur Reza., et al, (2025), Efficacy and Tolerability of Very Low-Dose Sacubitril/Valsartan in heart failure with reduced ejection fraction (HFrEF) Patients, J Clinical Cardiology and Cardiovascular Interventions, 8(9); DOI: 10.31579/2641-0419/487
Copyright: © 2025, Md. Alimur Reza. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 06 June 2025 | Accepted: 18 June 2025 | Published: 30 June 2025
Keywords: sacubitril/valsartan; heart failure with reduced ejection fraction (hfref); nt-probnp; tolerability; nyha functional class
Objective: This study aims to evaluate the efficacy and tolerability of Sacubitril/valsartan commenced at a very low dose in patients with Heart Failure and Reduced Ejection Fraction (HFrEF).
Methods: This was a prospective, real-world study conducted in 33 centres in Bangladesh on adult patients with symptomatic Heart failure and reduced ejection fraction (LVEF ≤ 40%) treated with a very low dose of Sacubitril/valsartan (12/13 mg) twice a day along with other standard treatment, with a 12-week follow-up. The primary endpoint was the mean change in NT-proBNP levels from baseline to week 12.
Results: The study included 655 patients with a mean age of 57.98±11.98 years. The mean NT-proBNP level showed a significant decline from 2867.15 pg/mL to 938.41 pg/mL (p<0.001). Notably, over 55% of patients achieved a reduction of 50% or more NT-proBNP. Concurrently, LVEF improved significantly from 34.80±6.7% at baseline to 39.20±6.4% at 12 weeks (p<0.001). There was also a significant reduction in left ventricular end-diastolic diameter, from 60.26±6.3 mm to 57.34±6.5 mm (p<0.001). Furthermore, more than 85% of patients exhibited favourable changes in the New York Heart Association functional class at 12 weeks (p<0.001). As there was no up-titration of doses, no patients experienced symptomatic hypotension or any other serious adverse events.
Conclusions: Very Low-dose sacubitril/valsartan demonstrates significant efficacy and tolerability in patients with HFrEF, as evidenced by marked reductions in NT-proBNP levels. The administration of a lower dosage may enhance patient tolerability and adherence to treatment; however, further controlled studies are necessary to confirm these findings.
ACEI – Angiotensin-Converting Enzyme Inhibitor AF – Atrial Fibrillation
ARB – Angiotensin Receptor Blocker
ARNI – Angiotensin Receptor–Neprilysin Inhibitor BD – Bis in Die (Twice Daily)
BMI – Body Mass Index
CCR – Creatinine Clearance Rate CVD – cardiovascular disease
eGFR – Estimated Glomerular Filtration Rate ESC – European Society of Cardiology
HF – Heart Failure
HFrEF – Heart Failure with Reduced Ejection Fraction HTN – Hypertension
IQR – Interquartile Range
LVEDD – Left Ventricular End-Diastolic Diameter LVEF – Left Ventricular Ejection Fraction
MI – Myocardial Infarction
MRA – Mineralocorticoid Receptor Antagonist
NT-proBNP – N-terminal pro-B-type Natriuretic Peptide NYHA – New York Heart Association
RCT – Randomized Controlled Trial SD – Standard Deviation
SGLT2 – Sodium-Glucose Cotransporter 2
SPSS – Statistical Package for the Social Sciences SV – Sacubitril/Valsartan
VLD – Very Low Dose
Heart failure (HF) represents a serious and life-threatening condition impacting an estimated 37.7 million individuals globally (Shah et al., 2017). It presents a significant public health burden due to its chronic nature, coupled with elevated rates of morbidity and mortality, along with frequent hospital admissions. In Bangladesh, heart failure accounts for approximately 28.5% of all cardiovascular diseases, underscoring a considerable public health challenge within the region (Rahman et al., 2017).
Despite adherence to guideline-directed medical therapy—including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists—patient outcomes remain suboptimal, particularly for those diagnosed with reduced ejection fraction (HFrEF) (Mozaffarian et al., 2015). Mortality rates and the risk of rehospitalization continue to be exceedingly high, thereby highlighting the urgent need for more effective treatment strategies.
Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), has emerged as a promising therapeutic alternative for patients with HFrEF. In the landmark PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, sacubitril/valsartan demonstrated a 20% relative risk reduction in cardiovascular death or heart failure hospitalization compared with enalapril, a standard ACEI (McMurray et al., 2014). These findings led to its incorporation into international clinical practice guidelines, with both the European Society of Cardiology (ESC) and American College of Cardiology (ACC)/American Heart Association (AHA) granting it a Class I recommendation for use in patients with chronic symptomatic HFrEF (Ponikowski et al., 2016; Yancy et al., 2017).
Despite strong endorsements for sacubitril/valsartan, its real-world utilization remains limited, with prescription rates falling short of expectations in clinical practice (Du et al., 2019; DeVore et al., 2018; Vicent et al., 2019; Pinto et al., 2019; Greene et al., 2018). Several factors contribute to this gap, many of which originate from treatment protocols used in pivotal trials such as PARADIGM-HF, where patients were required to tolerate a high dose of enalapril before transitioning to sacubitril/valsartan. In real-world settings, many patients are unable to tolerate such doses due to adverse effects like hypotension, renal dysfunction, or hyperkalemia (Oh et al., 2019; Wachter et al., 2019). As a result, clinicians often initiate sacubitril/valsartan at lower doses (50 mg or 100 mg twice daily), and up- titration to the recommended target dose of 200 mg twice daily is frequently not achieved. Observational data suggest that only 27% to 38% of patients reach the target dose in routine practice (Du et al., 2019; Vicent et al., 2019).
Initiating therapy in patients with heart failure with reduced ejection fraction is further complicated by risks such as symptomatic hypotension, renal impairment, and hyperkalemia—particularly in elderly patients or those with low baseline blood pressure or renal dysfunction—leading to delays or underdosing in clinical management (Greene et al., 2018). A low starting dose with a conservative up- titration schedule is recommended. The TITRATION trial shows that gradual dose escalation improves tolerability without affecting long-term efficacy (Desai et al., 2017). Similarly, the PARADIGM-HF trial indicates that patients unable to reach target doses still benefit clinically (McMurray et al., 2014). Real- world studies confirm that low-dose initiation increases acceptance in high-risk groups while allowing for future titration (Greene et al., 2018). A retrospective analysis by Amitabh et al. (2021) involving 45 of 278 patients revealed significant reductions in NT-proBNP levels across low-dose groups, suggesting that this approach can benefit those who are intolerant to higher doses. Additionally, a study by Hyoeun et al. (2020) showed comparable improvements in NT-proBNP levels and left ventricular ejection fraction for patients starting at a conservative 25 mg BID, with similar adverse event rates. Therefore, a low-dose initiation strategy for sacubitril/valsartan may enhance safety, adherence, and therapeutic outcomes in clinical practice.
Patients with HFrEF in Bangladesh often present with multiple comorbidities, including chronic kidney disease, low body weight, and hypotension, which can heighten the risk of adverse effects from standard doses of sacubitril/valsartan. Additionally, limited access to regular laboratory monitoring and follow-up in resource-constrained settings further complicates the safe initiation and titration of the drug. A low-dose approach may offer improved tolerability and greater feasibility for long-term use in this population. Moreover, economic constraints constitute a significant barrier to the widespread adoption of newer heart failure therapies, and initiating treatment at a very low dose may reduce upfront medication costs, improving accessibility and adherence. While global studies, such as the TITRATION trial and data from Korea and California, support the safety and effectiveness of initiating sacubitril/valsartan at lower-than-recommended doses (Desai et al., 2017; Hyoeun et al., 2020; Amitabh et al., 2021), local data are needed to validate this approach in the Bangladeshi population. Therefore, a region-specific study could provide valuable insights into optimizing heart failure treatment in low-resource settings. This study aims to evaluate the efficacy and tolerability of sacubitril/valsartan commenced at a very low dose in patients with HFrEF.
Study Design and Setting
This was a prospective, observational cohort study conducted to evaluate the real-world effectiveness and safety of sacubitril/valsartan (SV) in patients with HFrEF. The study was carried out across 33 centers in Bangladesh from November 2023 to October 2024. Adult patients diagnosed with HFrEF and prescribed SV as part of routine clinical care were enrolled and followed over a defined period of 12 weeks. All procedures were conducted in accordance with the ethical standards of the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines. Written informed consent was obtained from all participants prior to enrollment.
Study Participants & Procedures
A total of 655 patients diagnosed with symptomatic heart failure and reduced ejection fraction (left ventricular ejection fraction ≤ 40%) who received a very low dose of Sacubitril/valsartan (12/13 mg) administered twice daily, in conjunction with other standard treatments, were enrolled in the study. The inclusion criteria specified that subjects must be male or female adults aged 18 years or older, exhibit symptomatic heart failure characterized by New York Heart Association (NYHA) class II–IV, and present with a left ventricular ejection fraction of 40% or less, alongside a systolic blood pressure ranging from 90 to 100 mmHg. Patients with renal dysfunction defined as endogenous creatinine clearance rate (CCR), 30 ml/min/1.73 m2 and estimated glomerular filtration rate (eGFR)5.4 mmol/l, previous intolerance to recommended target doses of ACEI/ARBs, known history of angioedema, current hospitalization for conditions other than decompensated HF and serum potassium level >5.4 mmol/l were excluded.
At baseline, comprehensive sociodemographic data, clinical history, findings from physical examinations, and laboratory investigations—including NT-proBNP levels, serum creatinine, electrolytes, and liver function tests—were systematically collected. NT-proBNP levels were subsequently reassessed at the second follow-up to evaluate biochemical responses. Patients were monitored at 4 weeks and 12 weeks post-enrollment to assess adverse events, including hypotension, renal impairment, and hyperkalemia, as well as any instances of hospitalization or therapy discontinuation.
Study Outcomes
The primary endpoints of the study included the proportional change in NT-proBNP levels and the improvement in NYHA functional class by Week 12. The secondary endpoints encompassed alterations in left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD), cardiovascular mortality, hospital re-admission for heart failure, and all-cause mortality, all assessed by Week 12. Additionally, safety endpoints were defined as the percentage of patients withdrawn due to adverse events, as well as the incidence of both adverse events and serious adverse events from baseline to Week 12.
Statistical Analysis
All data were systematically entered and analyzed utilizing SPSS for Windows, version 25.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were employed to summarize the baseline and follow-up characteristics of the participants. Continuous variables were presented as mean ± standard deviation (SD), accompanied by the interquartile range (IQR), with comparisons made using the paired t-test, as appropriate based on the distribution. Categorical variables were reported as frequencies and percentages, with comparisons conducted using the Chi-square test. A p-value of less than 0.05 was deemed statistically significant for all analyses.
Study Population
A total of 914 patients diagnosed with HFrEF and treated with sacubitril/valsartan were initially enrolled in the study. Ultimately, 655 patients had comprehensive data available for both baseline and follow-up measurements of NT-proBNP. These 655 patients were included in the final analysis.
Sociodemographic Characteristics
Out of 655 patients included in the study, the majority were above 60 years (41.6%). The mean age of total patients was 57.98 ± 11.98 years. Males constituted 69.5% of the study population. Most patients had a healthy BMI (53.5%), while 38.9% were overweight and 4.5% were obese. Regarding smoking history, 43.2% were non-smokers, 40.2% were current smokers, and 18.6% were ex-smokers.
| Demographic characteristics | Frequency | Percentage |
| Age | ||
| <50> | 154 | 23.7% |
| 50-60 years | 226 | 34.7% |
| >60 years | 271 | 41.6% |
| Sex | ||
| Male | 455 | 69.50% |
| Female | 200 | 30.50% |
| BMI | ||
| Underweight | 14 | 3.10% |
| Healthy Weight | 239 | 53.50% |
| Overweight | 174 | 38.9% |
| Obesity | 20 | 4.50% |
| Smoking history | ||
| Non-smoker | 263 | 43.2% |
| Smoker | 233 | 40.2% |
| Ex-smoker | 113 | 18.6% |
| Co-morbidity | ||
| Stroke | 36 | 5.5% |
| Diabetes | 342 | 52.6% |
| MI | 355 | 54.6% |
| AF | 24 | 3.7% |
| Renal failure | 67 | 10.3% |
| HTN | 337 | 55.7% |
Table 1: Demographic characteristics of study populations
Changes in NT-proBNP
Figure 1 and Table 2 provide a summary of the changes observed with sacubitril/valsartan treatment in the primary outcome measure, NT-proBNP, which is an essential biomarker for evaluating the severity of heart failure. At baseline, the mean NT-proBNP level was recorded at 2,867.15 ± 3,817.46 pg/mL. After treatment, this value demonstrated a substantial decrease to 938.41 ± 1,470.22 pg/mL. This reduction was statistically significant (p < 0>Variables Baseline After 12 weeks P-value NT-proBNP (pg/mL); Mean± SD 2867.15 ± 3817.46 938.41 ± 1470.22 <0> LVEF (%); Mean± SD 34.80 ± 6.7 (%) 39.20 ± 6.4(%) <0> LVEDD (mm); Mean± SD 60.26 ± 6.3 57.34 ± 6.5 <0> Serum Sodium (mmol/L); Mean ± SD 137.92 ± 5.9 137.63 ± 4.2 0.150 Serum Potassium (mEq/L); Mean ± SD 4.24 ± 0.7 4.25 ± 0.6 0.983 Serum Creatinine (mg/dL); Mean ± SD 1.24 ± 0.4 1.18 ± 0.3 <0>
Table 2: Changes under treatment with Sacubitril/Valsartan after 12 weeks of follow-up
Figure 2. Changes after 12 weeks treatment with sacubitril/valsartan- mean NT-proBNP (A) level significantly decreased from 2867.15 pg/mL to 938.41 pg/mL (p<0>
Figure 2 shows the percentage changes across five categories related to the extent of decline or increase. Specifically, 29% of patients exhibited a ≥75
This prospective, multicenter, real-world study in Bangladesh assessed the effectiveness and safety of initiating very low-dose sacubitril/valsartan (12/13 mg twice daily) in patients with heart failure with reduced ejection fraction. The results demonstrate clinically meaningful improvements in NT-proBNP levels, LVEF, LVEDD, and NYHA functional class, while maintaining a favorable safety and tolerability profile. These findings are consistent with those reported in both landmark randomized controlled trials and observational studies.
In the PARADIGM-HF trial, sacubitril/valsartan significantly reduced the risk of cardiovascular death or heart failure hospitalization by 20% compared with enalapril (McMurray et al., 2014). Our study similarly showed a notable reduction in NT-proBNP levels—from 2867.15 pg/mL to 938.41 pg/mL (p< .001)—a key biomarker predictive of prognosis in HFrEF. Furthermore, 85% of patients demonstrated an improvement in NYHA class, indicating significant symptomatic benefit.
The present findings align with real-world evidence. For example, Amitabh et al. (2019) reported a significant reduction in NT-proBNP (3703 to 1478 ng/mL, p < .01) among patients in California on very low doses of sacubitril/valsartan. In Korea, Hyoeun et al. (2019) observed a similar NT-proBNP decline (2594 to 2199 pg/mL, p < .001), with no differences in outcomes between standard and very low-dose groups. These studies also reported improvement in NYHA functional class, consistent with our observations.
Jingwen et al. (2019) found a reduction in NT-proBNP (from 2495 to 943 pg/mL, p < .001), a rise in LVEF (from 35.4% to 43.0%, p < .001), and a decrease in LVEDD (from 63.7 to 60.4 mm, p < .01), mirroring our findings (LVEF: 34.80% to 39.20%, p < .001; LVEDD: 60.26 to 57.34 mm, p < .001).
Renal and electrolyte safety were also observed in our cohort. While Amitabh et al. (2019) noted a non- significant rise in serum creatinine and potassium, our study revealed a statistically significant reduction in serum creatinine (1.24 to 1.18 mg/dL; p < .001), with no significant changes in potassium levels. These findings are in line with those from Jingwen et al. (2019), who reported no significant changes in creatinine or potassium levels.
Adverse events in our study were infrequent and generally mild. Tolerable cough was most commonly reported (16.5% at baseline, declining to 9.6% at 12 weeks), followed by hypotension (6.6% to 3.4%) and angioedema (1.4% to 0.8%). Jingwen et al. (2019) reported hypotension in 60% of patients during up-titration, with minimal cough and no angioedema. Similarly, Hyoeun et al. study showed, the most common adverse event was hypotension, but there was no significant difference in the adverse events between the two dose-groups. The most common cause for intolerance during up-titration was dizziness, and more patients complained of dizziness in the SD group compared to the VLD group.
Across various clinical trials and real-world studies, the tolerability and discontinuation rates of sacubitril/valsartan have shown notable variation. In PARADIGM-HF and PARAGON-HF, discontinuation due to adverse events occurred in 10.7% and 25.3% of patients, respectively (McMurray et al., 2014; Solomon et al., 2019). The TRANSITION study showed lower discontinuation rates when therapy was initiated in-hospital (7.1% pre-discharge, 5.6% post-discharge) (Welsh et al., 2019). In contrast, real-world discontinuation rates are generally lower. For instance, Jin Joo et al. (2019) reported a 5.2% rate, Alberto et al. (2018) reported none, and Muhammad et al. (2020) reported a higher rate (19.4%) related to dose adjustments. Remarkably, in our study, no patient discontinued sacubitril/valsartan therapy during the follow-up period, indicating excellent tolerability and adherence.
Importantly, our cohort was initiated on sacubitril/valsartan without a run-in phase or prior tolerance of high-dose ACE inhibitors, unlike the PARADIGM-HF protocol. This deviation was necessitated by the clinical characteristics of our population, which included lower average BMI, higher baseline hypotension, and frequent comorbidities (e.g., diabetes, hypertension). These factors may explain both the need for low-dose initiation and the observed high tolerability.
This study has several limitations. First, the absence of a control group limits causal inference, as improvements cannot be definitively attributed to sacubitril/valsartan alone. Second, observational design is subject to potential confounders, such as variability in physician decision-making and adherence. Third, although multicenter, the study population was limited to Bangladesh, potentially reducing generalizability to broader populations. Fourth, the follow-up duration (12 weeks) may not capture long-term outcomes, including mortality and rehospitalization rates. Fifth, the use of echocardiography and laboratory parameters without centralized adjudication may introduce measurement bias.
The findings of this study support the therapeutic potential of initiating sacubitril/valsartan at a very low dose in patients with HFrEF, particularly in real-world clinical settings. Significant improvements in NT-proBNP levels, left ventricular function, and symptom burden, coupled with favorable tolerability, underscore the viability of low-dose initiation strategies—especially for patient populations with heightened sensitivity to standard dosages. Moreover, the enhanced tolerability profile may facilitate better treatment adherence. Nonetheless, these findings should be interpreted within the context of an observational design. Future randomized controlled trials are warranted to confirm the long-term efficacy, safety, and optimal dosing strategies of sacubitril/valsartan in diverse clinical populations.
The authors gratefully acknowledge the financial support provided by Beximco Pharmaceuticals Limited, Dhaka, Bangladesh, which was instrumental in facilitating the conduct of this study. The sponsor had no involvement in the study design, data collection, data analysis, interpretation of results, or the preparation and submission of the manuscript. The authors retained complete independence in all aspects of the research.
The authors declare no conflicts of interest
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
I would like to offer my testimony in the support. I have received through the peer review process and support the editorial office where they are to support young authors like me, encourage them to publish their work in your esteemed journals, and globalize and share knowledge globally. I really appreciate your journal, peer review, and editorial office.
Dear Agrippa Hilda- Editorial Coordinator of Journal of Neuroscience and Neurological Surgery, "The peer review process was very quick and of high quality, which can also be seen in the articles in the journal. The collaboration with the editorial office was very good."
I would like to express my sincere gratitude for the support and efficiency provided by the editorial office throughout the publication process of my article, “Delayed Vulvar Metastases from Rectal Carcinoma: A Case Report.” I greatly appreciate the assistance and guidance I received from your team, which made the entire process smooth and efficient. The peer review process was thorough and constructive, contributing to the overall quality of the final article. I am very grateful for the high level of professionalism and commitment shown by the editorial staff, and I look forward to maintaining a long-term collaboration with the International Journal of Clinical Case Reports and Reviews.
To Dear Erin Aust, I would like to express my heartfelt appreciation for the opportunity to have my work published in this esteemed journal. The entire publication process was smooth and well-organized, and I am extremely satisfied with the final result. The Editorial Team demonstrated the utmost professionalism, providing prompt and insightful feedback throughout the review process. Their clear communication and constructive suggestions were invaluable in enhancing my manuscript, and their meticulous attention to detail and dedication to quality are truly commendable. Additionally, the support from the Editorial Office was exceptional. From the initial submission to the final publication, I was guided through every step of the process with great care and professionalism. The team's responsiveness and assistance made the entire experience both easy and stress-free. I am also deeply impressed by the quality and reputation of the journal. It is an honor to have my research featured in such a respected publication, and I am confident that it will make a meaningful contribution to the field.
"I am grateful for the opportunity of contributing to [International Journal of Clinical Case Reports and Reviews] and for the rigorous review process that enhances the quality of research published in your esteemed journal. I sincerely appreciate the time and effort of your team who have dedicatedly helped me in improvising changes and modifying my manuscript. The insightful comments and constructive feedback provided have been invaluable in refining and strengthening my work".
I thank the ‘Journal of Clinical Research and Reports’ for accepting this article for publication. This is a rigorously peer reviewed journal which is on all major global scientific data bases. I note the review process was prompt, thorough and professionally critical. It gave us an insight into a number of important scientific/statistical issues. The review prompted us to review the relevant literature again and look at the limitations of the study. The peer reviewers were open, clear in the instructions and the editorial team was very prompt in their communication. This journal certainly publishes quality research articles. I would recommend the journal for any future publications.
Dear Jessica Magne, with gratitude for the joint work. Fast process of receiving and processing the submitted scientific materials in “Clinical Cardiology and Cardiovascular Interventions”. High level of competence of the editors with clear and correct recommendations and ideas for enriching the article.
We found the peer review process quick and positive in its input. The support from the editorial officer has been very agile, always with the intention of improving the article and taking into account our subsequent corrections.
My article, titled 'No Way Out of the Smartphone Epidemic Without Considering the Insights of Brain Research,' has been republished in the International Journal of Clinical Case Reports and Reviews. The review process was seamless and professional, with the editors being both friendly and supportive. I am deeply grateful for their efforts.
To Dear Erin Aust – Editorial Coordinator of Journal of General Medicine and Clinical Practice! I declare that I am absolutely satisfied with your work carried out with great competence in following the manuscript during the various stages from its receipt, during the revision process to the final acceptance for publication. Thank Prof. Elvira Farina
Dear Jessica, and the super professional team of the ‘Clinical Cardiology and Cardiovascular Interventions’ I am sincerely grateful to the coordinated work of the journal team for the no problem with the submission of my manuscript: “Cardiometabolic Disorders in A Pregnant Woman with Severe Preeclampsia on the Background of Morbid Obesity (Case Report).” The review process by 5 experts was fast, and the comments were professional, which made it more specific and academic, and the process of publication and presentation of the article was excellent. I recommend that my colleagues publish articles in this journal, and I am interested in further scientific cooperation. Sincerely and best wishes, Dr. Oleg Golyanovskiy.
Dear Ashley Rosa, Editorial Coordinator of the journal - Psychology and Mental Health Care. " The process of obtaining publication of my article in the Psychology and Mental Health Journal was positive in all areas. The peer review process resulted in a number of valuable comments, the editorial process was collaborative and timely, and the quality of this journal has been quickly noticed, resulting in alternative journals contacting me to publish with them." Warm regards, Susan Anne Smith, PhD. Australian Breastfeeding Association.
Dear Jessica Magne, Editorial Coordinator, Clinical Cardiology and Cardiovascular Interventions, Auctores Publishing LLC. I appreciate the journal (JCCI) editorial office support, the entire team leads were always ready to help, not only on technical front but also on thorough process. Also, I should thank dear reviewers’ attention to detail and creative approach to teach me and bring new insights by their comments. Surely, more discussions and introduction of other hemodynamic devices would provide better prevention and management of shock states. Your efforts and dedication in presenting educational materials in this journal are commendable. Best wishes from, Farahnaz Fallahian.
Dear Maria Emerson, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews, Auctores Publishing LLC. I am delighted to have published our manuscript, "Acute Colonic Pseudo-Obstruction (ACPO): A rare but serious complication following caesarean section." I want to thank the editorial team, especially Maria Emerson, for their prompt review of the manuscript, quick responses to queries, and overall support. Yours sincerely Dr. Victor Olagundoye.
Dear Ashley Rosa, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews. Many thanks for publishing this manuscript after I lost confidence the editors were most helpful, more than other journals Best wishes from, Susan Anne Smith, PhD. Australian Breastfeeding Association.
Dear Agrippa Hilda, Editorial Coordinator, Journal of Neuroscience and Neurological Surgery. The entire process including article submission, review, revision, and publication was extremely easy. The journal editor was prompt and helpful, and the reviewers contributed to the quality of the paper. Thank you so much! Eric Nussbaum, MD
Dr Hala Al Shaikh This is to acknowledge that the peer review process for the article ’ A Novel Gnrh1 Gene Mutation in Four Omani Male Siblings, Presentation and Management ’ sent to the International Journal of Clinical Case Reports and Reviews was quick and smooth. The editorial office was prompt with easy communication.
Dear Erin Aust, Editorial Coordinator, Journal of General Medicine and Clinical Practice. We are pleased to share our experience with the “Journal of General Medicine and Clinical Practice”, following the successful publication of our article. The peer review process was thorough and constructive, helping to improve the clarity and quality of the manuscript. We are especially thankful to Ms. Erin Aust, the Editorial Coordinator, for her prompt communication and continuous support throughout the process. Her professionalism ensured a smooth and efficient publication experience. The journal upholds high editorial standards, and we highly recommend it to fellow researchers seeking a credible platform for their work. Best wishes By, Dr. Rakhi Mishra.
Dear Jessica Magne, Editorial Coordinator, Clinical Cardiology and Cardiovascular Interventions, Auctores Publishing LLC. The peer review process of the journal of Clinical Cardiology and Cardiovascular Interventions was excellent and fast, as was the support of the editorial office and the quality of the journal. Kind regards Walter F. Riesen Prof. Dr. Dr. h.c. Walter F. Riesen.
Dear Ashley Rosa, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews, Auctores Publishing LLC. Thank you for publishing our article, Exploring Clozapine's Efficacy in Managing Aggression: A Multiple Single-Case Study in Forensic Psychiatry in the international journal of clinical case reports and reviews. We found the peer review process very professional and efficient. The comments were constructive, and the whole process was efficient. On behalf of the co-authors, I would like to thank you for publishing this article. With regards, Dr. Jelle R. Lettinga.
Dear Clarissa Eric, Editorial Coordinator, Journal of Clinical Case Reports and Studies, I would like to express my deep admiration for the exceptional professionalism demonstrated by your journal. I am thoroughly impressed by the speed of the editorial process, the substantive and insightful reviews, and the meticulous preparation of the manuscript for publication. Additionally, I greatly appreciate the courteous and immediate responses from your editorial office to all my inquiries. Best Regards, Dariusz Ziora
